- |||||||||| Biomarker, Review, Journal: Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. (Pubmed Central) - Apr 26, 2024
In HS, TNF-?, IL-1?, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra...AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab...CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine...Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.
- |||||||||| Retrospective data, Review: Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis. (Pubmed Central) - Apr 25, 2024
Two low-dose groups of oral formulations (ritlecitinib 10mg and ivarmacitinib 2mg) and two topical formulations (delgocitinib ointment and ruxolitinib cream) appeared to be relatively ineffective against moderate-to-severe AA...Regarding the SALT50 response, brepocitinib 30mg ranked highest (sucra = 0.9567), followed by ritlecitinib 50mg (sucra = 0.8689) and deuruxolitinib 12mg (sucra = 0.7690)...To enhance the applicability and accuracy of our research, further head-to-head trials with longer follow-up periods are needed. Systematic Review Registration: identifier [CRD42022368012].
- |||||||||| Review, Journal: Interleukin antagonists for atopic dermatitis: a new era of therapy. (Pubmed Central) - Apr 24, 2024
To date, the IL-4Ra-inhibitor dupilumab, and the IL-13 inhibitor tralokinumab, have gained regulatory approval in Europe for the treatment of moderate-to-severe AD, while more than 70 new therapeutics are currently in development...There is still an unmet need for real-world-evidence studies and head-to-head studies for both currently available and future agents in AD treatment. Establishing predictive biomarkers of treatment response in a disorder of such considerable heterogenicity might help physicians pursue a patient-tailored therapeutic response.
- |||||||||| Desonate (desonide gel) / LEO Pharma
Journal: Filament coating system assists recovery of ablative fCO laser treatment: A split-face clinical observation. (Pubmed Central) - Apr 24, 2024
Establishing predictive biomarkers of treatment response in a disorder of such considerable heterogenicity might help physicians pursue a patient-tailored therapeutic response. Filament coating system was effective, safe, convenient, and economic in assisting recovery of ablative fCO2 laser, which might be a new option for additional nursing procedure.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health
Journal: Gingerenone A Attenuates Ulcerative Colitis via Targeting IL-17RA to Inhibit Inflammation and Restore Intestinal Barrier Function. (Pubmed Central) - Apr 19, 2024
Importantly, lentivirus-mediated IL-17RA/Act1 knock-down or GA co-treatment with brodalumab/ixekizumab significantly impairs the protective effects of GA against DSS-induced inflammation and barrier dysfunction, suggesting a critical role of IL-17RA signaling for GA-mediated protection against UC. Overall, these results indicate that GA is an effective agent against UC mainly through the direct binding of IL-17RA to inhibit inflammatory signaling activation.
- |||||||||| Review, Journal: Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis. (Pubmed Central) - Apr 17, 2024
High-dose upadacitinib was shown in another meta-analysis to be most effective in the measured outcomes but had the highest frequency of adverse events...Treatment can be individualized based on potency, adverse side effects, mechanism of action, and administration preference. Ongoing research continues to expand treatment options for AD.
- |||||||||| Retrospective data, Review: Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 17, 2024
This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Matching-Adjusted Indirect Comparison of the Efficacy at Week (Pubmed Central) - Apr 13, 2024
Certainly, furthers studies will allow for better characterization of biologics' profile, in order to administer the right drug for the right patients at the right moment. The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32
- |||||||||| Review, Journal: Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. (Pubmed Central) - Apr 13, 2024
Ruxolitinib (n?=?6) and tofacitinib (n?=?6) were the most often studied topical JAKi, followed by delgocitinib (n?=?1)...No serious or clinically meaningful hematology or thromboembolic events were detected. Treatment of vitiligo with oral or topical JAKi seems to be promising and the growing evidence shows a favorable risk-benefit profile.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. (Pubmed Central) - Apr 8, 2024
Topical probiotics reduce S. aureus abundance in AD lesional skin, yet for moderate-severe disease, these therapies may not reduce AD severity scores to the standard of biologics. Dupilumab and tralokinumab target key inflammatory pathways in AD and modulate the skin microbiome, further improving disease severity.
- |||||||||| Innohep (tinzaparin) / LEO Pharma
Enrollment change, Trial completion date, Trial termination: TILE: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (clinicaltrials.gov) - Apr 4, 2024
P4, N=9, Terminated,
Dupilumab and tralokinumab target key inflammatory pathways in AD and modulate the skin microbiome, further improving disease severity. N=60 --> 9 | Trial completion date: Oct 2024 --> Jan 2024 | Recruiting --> Terminated; funding discontinued
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2?years. (Pubmed Central) - Apr 2, 2024
P3
This representative, non-interventional study confirms the short- and long-term effectiveness and safety profile of brodalumab in the management of psoriasis in daily practice as well as in relevant treatment pathways. Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13 in the pathogenesis of AD.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
The calpain/ABCA1 pathway drives mast cell- initiated vascular leakage and inflammation in the skin. (Exhibit Hall F1; Poster Board Number: B746) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1908;
Corroborating this finding, global ABCA1 blockade with FDA-approved glyburide similarly reduced inflammation induced by MC903. Collectively, these data suggest that targeting the calpain/ABCA1 pathway may open new therapeutic avenues for MC -mediated inflammation in the skin.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Novel Oral Treatment for Atopic Dermatitis: Allosteric Modulation of GABAA Receptor Signaling (Exhibit Hall F1; Poster Board Number: B646) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1261;
The administration of GABAA receptor ligands demonstrated a substantial reduction in ear inflammation, ear thickness, and ear scratching in the murine model for AD. This research provides promising insights into the development of a novel and effective oral treatment for AD.
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, ingenol disoxate (LEO 43204) / LEO Pharma
Review, Journal: Topical Immunotherapy for Actinic Keratosis and Field Cancerization. (Pubmed Central) - Mar 28, 2024
The analysis extends to optimal combination, focusing on cryoimmunotherapy as the most relevant. New immunotherapies include resimiquimod, ingenol disoxate, N-phosphonacetyl-L-aspartate (PALA), or anti-PD1 that have shown promising results, although more studies are needed in order to standardize their use.
- |||||||||| Corectim (delgocitinib) / Japan Tobacco, LEO Pharma
Journal: Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. (Pubmed Central) - Mar 24, 2024
P3
Psychometric analyses were performed using data from a sample of 280 patients with moderate to severe CHE from a phase 3 trial of delgocitinib cream, pooled across treatment groups...These findings provide evidence the IGA-CHE scale has strong reliability, construct validity, and ability to detect change, supporting its use as an endpoint in CHE clinical trials and clinical practice. Based on the evidence, 2-level changes in IGA-CHE score are considered a conservative meaningful change threshold; however, findings also indicate 1-level change in IGA-CHE scores reflects a clinically meaningful improvement for patients.Clinical trial registration: NCT04871711.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
The calpain/ABCA1 pathway drives mast cell- initiated vascular leakage and inflammation in the skin. (Room W179) - Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_389;
Corroborating this finding, global ABCA1 blockade with FDA-approved glyburide similarly reduced inflammation induced by MC903. Collectively, these data suggest that targeting the calpain/ABCA1 pathway may open new therapeutic avenues for MC -mediated inflammation in the skin.
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Siliq (brodalumab) / Bausch Health
Journal: Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis. (Pubmed Central) - Mar 22, 2024
inhibitors (etanercept) and interleukin-17A receptor inhibitors (brodalumab) but not methotrexate and interleukin-12/23 inhibitors. Psoriasis patients can be assorted into three subtypes with different molecular and cellular characteristics based on the heterogeneity of the skin's immune cells and the stroma, determining the clinical responses of conventional therapies.
- |||||||||| isotretinoin topical (TMB-001) / LEO Pharma
Enrollment closed, Enrollment change: The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis (clinicaltrials.gov) - Mar 22, 2024
P3, N=209, Active, not recruiting,
Psoriasis patients can be assorted into three subtypes with different molecular and cellular characteristics based on the heterogeneity of the skin's immune cells and the stroma, determining the clinical responses of conventional therapies. N=142 --> 209 | Recruiting --> Active, not recruiting
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: Epidermal loss of Bcl6 exacerbates MC903-induced atopic dermatitis-like skin inflammation. (Pubmed Central) - Mar 19, 2024
In addition, Bcl6 expression is decreased in the epidermis of lesional skin from MC903-induced AD-like skin inflammation in mice. These results strongly suggest that Bcl6 downregulation in keratinocytes contributes to the development and aggravation of AD-like skin inflammation in mice.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: Chronic Gut Inflammation and Dysbiosis in IBS: Unraveling Their Contribution to Atopic Dermatitis Progression. (Pubmed Central) - Mar 17, 2024
A subsequent MC903 challenge on the right cheek lasting for 7 days revealed more severe AD symptoms in IBS mice compared to controls...Notably, an increased abundance of Alistipes in the feces of IBS mice correlated with heightened systemic and localized inflammation in both the gut and skin. These findings collectively indicate that chronic gut inflammation and microbial dysbiosis in IBS are critical factors exacerbating AD, highlighting the integral relationship between gut and skin health.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: Calycosin enhances treg differentiation for alleviating skin inflammation in atopic dermatitis. (Pubmed Central) - Mar 15, 2024
This article provides evidence of strong content validity and psychometric validity and shows improvements of???4 points on 7-day average HESD scores represent clinically meaningful, important changes. The study provides insights into the mechanistic pathways through which CA exerts its anti-inflammatory effects, particularly through promoting Treg cell differentiation and inhibiting Th17
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
EOSINOPHILIC ESOPHAGITIS ALTERS THE EPITHELIAL AND IMMUNOLOGICAL LANDSCAPE TO LIMIT CARCINOGENESIS IN THE MURINE ESOPHAGUS (103AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6041;
Continuing analysis will validate these findings in vivo and examine alterations in activation states of immune cells between conditions that may contribute to anti-tumorigenic activity associated with EoE inflammation. Furthermore, complete evaluation of differential gene expression as well chromatin availability can identify novel targets for therapeutic action in esophageal carcinoma.
- |||||||||| Jakafi (ruxolitinib) / Incyte, Dovonex (calcipotriol) / LEO Pharma, Novartis
A NOVEL STAT3/6-MEDIATED MITOCHONDRIAL-IMMUNE PATHWAY CONTRIBUTES TO EOE PATHOGENESIS (103AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6036;
EoE was induced in mice using MC903/Ovalbumin (OVA) and peeled epithelium was evaluated for mitochondrial DNA (mtDNA) by qPCR and MTCO1 by immunoblotting...Ruxolitinib suppressed STAT6 Tyr 641 and STAT3 Ser 727 phosphorylation mediated by either IL-4 or IL-13... IL-13 and IL-4 in the EoE inflammatory milieu activate STAT3/6 signaling, increasing mitochondria in esophageal epithelial cells, and promoting EoE inflammation.
- |||||||||| Innohep (tinzaparin) / LEO Pharma
CITRATE-CONTAINING DIALYSATE FOR HIGH CLOTTING RISK HAEMODIALYSIS PATIENTS (SUN-206; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1335;
For patients with high clotting risks, switching from acetate- to citrate-containing dialysate allowed completion of the whole haemodialysis session without utilising an extra dose of low molecular weight heparin at mid-dialysis, although sub-clinical clotting was more severe. This is clinically significant as patients with both high bleeding and clotting risk can potentially keep a lower level of anticoagulation for their haemodialysis.
|
